Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA
neffy (epinephrine nasal spray) delivered a PK and PD profile greater than or similar to that of IM epinephrine after extreme nasal challenge, reports ARS Pharmaceuticals.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose
Your daily dose of the clinical news you may have missed.
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.
How do Americans Handle Being Sick?
A recent survey reveals some surprising facts about who handles illness better - men or women.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Weight Management Treatments Underused among Primary Care Patients with Obesity: Daily Dose
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
Salt Substitute Lowers Risk of Hypertension among Older Adults with Normal Blood Pressure
Older adults with normal BP levels in China were approximately 40% less likely to develop HTN when using a salt substitute for 2 years, according to a new study.
Women with IBD at Risk for Reduced Fertility Even During Clinical Disease Remission, Study Suggests
Histologic inflammation was associated with reduced fertility whether IBD disease was active or quiescent in a nationwide study of Swedish women aged 15 to 44 years.
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Persons with T2D, NAFLD: Daily Dose
Omalizumab Granted First FDA Indication for Children and Adults with Multiple Food Allergies
The OUtMATCH trial showed that individuals as young as age 1 year could tolerate small amounts of peanut and other allergens without an allergic reaction.
Atlantic Health System Tests Novel CAR-T Cell Therapy for Lupus in First US Patient
In the open-label, phase 1 study, participants' own T cells will be extracted and engineered to target and eliminate autoreactive B cells and to potentially reset the immune system.
Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose
